#AIEye #Podcast 714: #Stocks discussed: (OTCPINK: $GTCH) (NYSE: $PLTR) #artificialintelligence
GBT Releases New Version of Hippocrates Web App, and Palantir Announces $99.9M Contract with US Army Research Lab for AI/ML
Global #AI in #DrugDiscovery to Reach $4B by 2027
Vancouver, Kelowna, Delta, BC – July 28, 2022 – Investorideas.com, a global investor news source covering Artificial Intelligence (AI) brings you today’s edition of The AI Eye-watching stock news, deal tracker and advancements in artificial intelligence – featuring technology company GBT Technologies Inc. (OTCPINK:GTCH).
Listen to today’s podcast:
https://www.investorideas.com/Audio/Podcasts/2022/072822-AI-Eye.mp3
Read this in full at https://www.investorideas.com/news/2022/artificial-intelligence/07281GTCH-PLTR.asp
Today’s Column- The AI Eye- Watching stock news, deal tracker and advancements in artificial intelligence
Stocks discussed: (OTCPINK:GTCH) (NYSE:PLTR)
GBT Technologies Inc. (OTC PINK:GTCH) has announced that it is releasing a new version of the web application for its Hippocrates machine learning driven health content provider. The new application will leverage the company’s Avant! AI engine to “provide intelligent internet search, providing answers for general or specific health related questions.” Danny Rittman, GBT’s CTO, explained:
"This is only one of the many possible implementations of our core Avant! AI technology. The AI system is targeted to understand a user's question, analyzing the information and providing a targeted response. Hippocrates' new release is equipped with an initial vast amount of health-related data and is situated to cognitively grow its knowledge base over time, learning from its own experiences or by training, the same way a human does. We invested vast efforts with the new release, incorporating professional, accredited data from governmental and medical documentation resources. The current release is aimed to provide a first line of health-related information. In addition, it offers Avant! intelligent internet search to provide answers and information for health-related questions. The system is not aiming to replace physicians but to provide first line health information and guidelines. We also plan to seek clinics and hospitals as partners to provide an expert assistant in specific domains, for example cardiology or pediatrics expertise.”
Palantir Technologies Inc. (NYSE:PLTR) has announced a two-year contract worth $99.9 million USD with the U.S. Army Research Laboratory to implement data and artificial intelligence (AI)/machine learning (ML) capabilities for users across the combatant commands (COCOMs). Akash Jain, President of Palantir USG, said:
"Maintaining a leading edge through technology is foundational to our mission and partnership with the Army Research Laboratory. Our nation’s armed forces require best-in-class software to fulfill their missions today while rapidly iterating on the capabilities they will need for tomorrow’s fight. We are honored to support this critical work by teaming up to deliver the most advanced operational AI capabilities available with dozens of commercial and public sector partners."
Global AI in Drug Discovery to Reach $4B by 2027
A report published by Markets and Markets finds that the global AI in Drug Discovery market is projected to grow from $600 million USD in 2022 to $4 billion by 2027, registering a compound annual growth rate (CAGR) of 45.7 percent in the forecast period. The following excerpt from the report’s description outlines the significance of Deep Learning as a driving aspect of the market:
Based on type, the machine learning technology segment further segmented into deep learning, supervised learning. reinforcement learning, unsupervised learning, and other machine learning technologies. Deep learning segment accounted for the largest share of the market in 2021, and this segment is also expected to grow at the highest CAGR during the forecast period. Deep learning helps in managing data in a consistent manner, saves time, reduces the chances of errors in the drug discovery process, and reduces the workload for end users are some of the key factors for the market growth of this segment.
Sam Mowers, Investorideas.com
Read and hear other editions of the AI Eye
For a list of artificial intelligence stocks on Investorideas.com visit here
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com publishes breaking stock news, third party stock research, guest posts and original articles and podcasts in leading stock sectors. Learn about investing in stocks and get investor ideas in cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy, gaming and more. Investor Idea’s original branded content includes podcasts and columns : Crypto Corner , Play by Play sports and stock news , Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast , Cleantech and Climate Change , Exploring Mining , Betting on Gaming Stocks Podcast and the AI Eye Podcast.
The Investorideas.com podcasts are also available on Apple Podcasts , Audible , Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio, Google Podcasts and most audio platforms available.
Visit the Podcast page at Investorideas.com: https://www.investorideas.com/Audio/
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
Disclosure: GTCH is a paid for AI featured stock on our site. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
The AI Eye- Watching stock news, deal tracker and advancements in artificial intelligence is an original content brand of Investorideas.com
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Contact Investorideas.com
800 665 0411
Get more Technology stock investor ideas - news, articles, podcasts and stock directories
No comments:
Post a Comment